Published in Gut on April 24, 2008
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol (2015) 2.64
JC virus antibody status underestimates infection rates. Ann Neurol (2013) 1.30
Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol (2015) 1.21
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol (2010) 1.02
Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant (2009) 0.99
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Ther Clin Risk Manag (2014) 0.85
Natalizumab and PML: a risky business? Gut (2008) 0.85
Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol (2014) 0.81
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
An evidence-based review of natalizumab therapy in the management of Crohn's disease. Ther Clin Risk Manag (2009) 0.77
Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis (2013) 0.75
Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y) (2014) 0.75
Progressive multifocal leukoencephalopathy in autoimmune disorders. Gut (2009) 0.75
Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study. Front Microbiol (2016) 0.75
Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y) (2012) 0.75
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut (2006) 8.08
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther (2012) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Current status of genetics research in inflammatory bowel disease. Genes Immun (2005) 2.29
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Predicting relapse in Crohn's disease: a biopsychosocial model. Gut (2008) 2.01
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr (1999) 1.88
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1998) 1.60
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med (1998) 1.56
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Pulmonary haemorrhage as a predominant cause of death in leptospirosis in Seychelles. Trans R Soc Trop Med Hyg (2000) 1.54
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet (1990) 1.49
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
Varicella-zoster virus infection associated with acute liver failure. Clin Infect Dis (1998) 1.47
Influence of nutritional substrates on the formation of volatiles by the fecal flora. Gastroenterology (1991) 1.45
IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol (2000) 1.45
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther (2005) 1.45
The Dutch guidelines for treatment with infliximab for Crohn's disease. Neth J Med (2006) 1.44
Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut (1995) 1.42
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr (1999) 1.42
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis (2001) 1.41
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
Controlled trial of YAG laser treatment of upper digestive hemorrhage. Gastroenterology (1982) 1.39
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Sexually transmitted infections among married women in Dhaka, Bangladesh: unexpected high prevalence of herpes simplex type 2 infection. Sex Transm Infect (2001) 1.39
Helicobacter pylori infection and growth delay in older children. Arch Dis Child (1997) 1.39
Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies. Aliment Pharmacol Ther (2007) 1.39
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. Gut (1985) 1.38